Methotrexate with Dexlansoprazole Interaction Details


Brand Names Associated with Methotrexate

  • Amethopterin
  • Methotrexate
  • MTX
  • Rheumatrex®
  • Trexall®

Brand Names Associated with Dexlansoprazole

  • Dexilant® (formerly available as Kapidex®)
  • Dexlansoprazole

Medical Content Editor
Last updated Nov 17, 2023


Curious for more information about this interaction?

Ask our pharmacists directly!

Reach out to us

Interaction Effect

Increased risk of methotrexate toxicity


Interaction Summary

Although not studied specifically with dexlansoprazole, concomitant administration of methotrexate and some proton pump inhibitors (pantoprazole, lansoprazole, omeprazole, or esomeprazole) resulted in a 6.7-fold increased risk of delayed methotrexate elimination in a retrospective study of 79 cancer patients. Of cycles with delayed methotrexate elimination, 53.1% had a concomitantly administered proton pump inhibitor. In addition, plasma methotrexate concentrations were significantly greater at each time point (24, 48, and 72 hours) in patients with delayed elimination compared with patients without delayed elimination (p less than 0.01) . Use caution when administering high-dose methotrexate to patients receiving proton pump inhibitors . During high-dose methotrexate administration, consider temporarily stopping rabeprazole therapy . Closely monitor patients for signs and symptoms of methotrexate toxicity.


Severity

Major


Onset

Rapid


Evidence

Theoretical


How To Manage Interaction

Use caution when administering high-dose methotrexate to patients receiving proton pump inhibitors as concomitant administration of methotrexate (primarily high-dose) and proton pump inhibitors may cause delayed elimination of methotrexate and/or its metabolite and subsequent methotrexate toxicity . For patients on concomitant therapy, consider temporarily stopping rabeprazole during high-dose methotrexate administration , and closely monitor patients for signs and symptoms of methotrexate toxicity.


Mechanism Of Interaction

Decreased renal elimination of methotrexate by dexlansoprazole


Literature Reports

A) A retrospective, non-interventional cohort study (n=79) revealed a 6.7-fold increased risk of delayed methotrexate elimination with concomitant use of a proton pump inhibitor. Patients with various types of cancer (mean age, 48.8 years; range, 16 to 76 years) received cycles of high-dose IV methotrexate (greater than 1 g/m(2)). Cycles with avoidable causes for delayed methotrexate elimination were excluded from analysis. Delayed methotrexate elimination was defined as plasma methotrexate concentrations greater than 15, 1.5, and/or 0.15 mcmol/L at 24, 48, and 72 hours, respectively. Of 197 cycles, delayed methotrexate elimination was noted in 16% (32/197) of cycles. Of the cycles with delayed methotrexate elimination, concomitant use of a proton pump inhibitor (pantoprazole, lansoprazole, omeprazole, or esomeprazole) was significantly greater compared with cycles without delayed methotrexate elimination (53.1% vs 15%; p less than 0.001; odds ratio 6.66; 95% confidence interval, 3.13 to 14.17). Plasma methotrexate concentrations were significantly greater at each time point (24, 48, and 72 hours) in patients with delayed elimination compared with patients without delayed elimination (p less than 0.01) .

Methotrexate Overview

  • Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments. Methotrexate is also used along with rest, physical therapy, and sometimes other medications to treat severe active rheumatoid arthritis (RA; a condition in which the body attacks its own joints, causing pain, swelling, and loss of function) that cannot be controlled by certain other medications. Methotrexate is also used to treat certain types of cancer including cancers that begin in the tissues that form around a fertilized egg in the uterus, breast cancer, lung cancer, certain cancers of the head and neck, certain types of lymphoma, and leukemia (cancer that begins in the white blood cells). Methotrexate is in a class of medications called antimetabolites. Methotrexate treats cancer by slowing the growth of cancer cells. Methotrexate treats psoriasis by slowing the growth of skin cells to stop scales from forming. Methotrexate may treat rheumatoid arthritis by decreasing the activity of the immune system.

See More information Regarding Methotrexate

Dexlansoprazole Overview

  • Dexlansoprazole is used to treat the symptoms of gastroesophageal reflux disease (GERD; a condition in which backward flow of acid from the stomach causes heartburn and possible injury of the esophagus [tube between the throat and stomach]) in adults and children 12 years of age and older. It is also used to treat esophagitis (swelling that may damage tissues of the esophagus) in adults and children 12 years of age and older. Dexlansoprazole is used for the maintenance treatment of esophagitis and healing in adults and children 12 years of age and older. Dexlansoprazole is in a class of medications called proton pump inhibitors. It works by decreasing the amount of acid made in the stomach.

See More information Regarding Dexlansoprazole

Return To Our Drug Interaction Homepage


Feedback, Question Or Comment About This Information?

Ask , our medical editor, directly! He's always more than happy to assist.


Definitions

Severity Categories

Contraindicated

These drugs, generally, should not be used together simultaneously due to the high risk of severe adverse effects. Combining these medications can lead to dangerous health outcomes and should be strictly avoided unless otherwise instructed by your provider.


Major

This interaction could result in very serious and potentially life-threatening consequences. If you are taking this drug combination, it is very important to be under close medical supervision to minimize severe side effects and ensure your safety. It may be necessary to change a medication or dosage to prevent harm.


Moderate

This interaction has the potential to worsen your medical condition or alter the effectiveness of your treatment. It's important that you are monitored closely and you potentially may need to make adjustments in your treatment plan or drug dosage to maintain optimal health.


Minor

While this interaction is unlikely to cause significant problems, it could intensify side effects or reduce the effectiveness of one or both medications. Monitoring for changes in symptoms and your condition is recommended, and adjustments may be made if needed to manage any increased or more pronounced side effects.


Onset

Rapid: Onset of drug interaction typically occurs within 24 hours of co-administration.

Delayed: Onset of drug interaction typically occurs more than 24 hours after co-administration.


Evidence

Level of documentation of the interaction.

Established: The interaction is documented and substantiated in peer-reviewed medical literature.

Theoretical: This interaction is not fully supported by current medical evidence or well-documented sources, but it is based on known drug mechanisms, drug effects, and other relevant information.


How To Manage The Interaction

Provides a detailed discussion on how patients and clinicians can approach the identified drug interaction as well as offers guidance on what to expect and strategies to potentially mitigate the effects of the interaction. This may include recommendations on adjusting medication dosages, altering the timing of drug administration, or closely monitoring for specific symptoms.

It's important to note that all medical situations are unique, and management approaches should be tailored to individual circumstances. Patients should always consult their healthcare provider for personalized advice and guidance on managing drug interactions effectively.


Mechanism Of Interaction

The theorized or clinically determined reason (i.e., mechanism) why the drug-drug interaction occurs.


Disclaimer: The information provided on this page is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding your specific circumstances and medical conditions.

Where Does Our Information Come From?

Information for our drug interactions is compiled from several drug compendia, including:

The prescribing information for each drug, as published on DailyMED, is also used. 

Individual drug-drug interaction detail pages contain references specific to that interaction. You can click on the reference number within brackets '[]' to see what reference was utilized.

The information posted is fact-checked by HelloPharmacist clinicians and reviewed quarterly.